2 completed, 2 terminated. 3 Phase 3, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Terminated 2, Completed 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Ancrod: new trials by email Literature Review of Ancrod trials Research Report on Ancrod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss Ancrod, Saline solution - Hearing Loss, Deafness | Phase 1 / Phase 2 | Completed | Nordmark Arzneimittel GmbH & Co. KG | 31 | 2013-05-01 | 2018-12-21 |
| ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke Ancrod (Viprinex), Placebo - Stroke, Cerebral Ischemia | Phase 3 | Terminated | Neurobiological Technologies | 311 | 2006-03-01 | 2010-01-12 |
| Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke Ancrod (Viprinex), Placebo - Stroke, Cerebral Ischemia | Phase 3 | Terminated | Neurobiological Technologies | 277 | 2005-09-01 | 2009-12-23 |
| Intravenous Ancrod for the Treatment of Acute Ischemic Stroke Within 6 Hours After Onset of Symptoms Ancrod - Brain Infarction, Cerebral Ischemia | Phase 3 | Completed | Heidelberg University | 2006-06-22 |
Brain Infarction (3) · Brain Ischemia (3) · Stroke (3) · Deafness (1) · Ear Diseases (1) · Hearing Disorders (1) · Hearing Loss (1) · Hearing Loss, Sensorineural (1) · Vascular Diseases (1)
Neurobiological Technologies (2) · Heidelberg University (1) · Nordmark Arzneimittel GmbH & Co. KG (1)
Czechia (3) · Australia (2) · Poland (2) · Russia (2) · South Africa (2) · United States (2) · Austria (1) · Canada (1) · Germany (1) · Israel (1) · Netherlands (1) · New Zealand (1) · Slovakia (1) · Switzerland (1) · Taiwan (1)
Warren Wasiewski, M.D. (2) · Jean M Orgogozo, MD (1) · M G Hennerici, MD (1) · Martin Canis, MD PhD (1)